Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.22.1
Commitments and Contingencies (Details)
 1 Months Ended 9 Months Ended
May 11, 2021
item
Apr. 15, 2021
item
Jan. 31, 2022
USD ($)
Dec. 31, 2019
USD ($)
Feb. 28, 2022
USD ($)
D
agreement
Dec. 31, 2021
USD ($)
May 31, 2021
USD ($)
Contractual Obligation, Fiscal Year Maturity [Abstract]              
2022 (3 months remaining)         $ 2,418,000    
Number of license agreements | agreement         2    
Accrued license fee         $ 400,000    
Prepaid royalties             $ 100,000
Research, Development And Manufacturing Agreements With Samsung [Member]              
Loss Contingencies [Line Items]              
Forecast period         3 years    
Amount of material breach of' Master Services and Project Specific Agreements           $ 13,500,000  
Additional Contractual Obligation     $ 22,800,000        
Period for curing breach of contract     45 days        
Termination notice period     45 days        
Contractual Obligation         $ 232,789,000    
Contractual Obligation, Fiscal Year Maturity [Abstract]              
2023         32,221,000    
2024         121,750,000    
2025         76,400,000    
Total         232,789,000    
Termination of one trail | Maximum              
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Potential penalties         200,000    
Termination of all trails | Maximum              
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Potential penalties         600,000    
Termination of all trails | Minimum              
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Potential penalties         $ 20,000.0    
License Agreements With Vyera Pharmaceuticals, LLC              
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Amount payable upon achievement of sales and regulatory milestone       $ 87,000,000.0      
Percentage of royalty payable by the counter party       50.00%      
Term of arrangement       10 years      
Term of arrangement, after first commercial sale       2 years      
Number of days of prior written notice | D         180    
Supply And Distribution Agreement with Chiral Pharma Corporation [Member] | Covid 19 [Member]              
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Right to distribute and sell number of drugs | item   200,000          
Supply And Distribution Agreement With Macleods Pharmaceuticals Ltd. [Member] | Covid 19 [Member]              
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Right to distribute and sell number of drugs | item 200,000            
Progenics Purchase Agreement [Member]              
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Amount of milestone payments payable         $ 5,000,000.0    
Amount payable upon filing BLA with FDA         500,000    
Amount payable upon FDA approval         500,000    
Annual maintenance fees         $ 150,000    
Progenics Purchase Agreement [Member] | Royalty Payable in Initial 10 Years [Member]              
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Percentage of royalty payable         5.00%    
Progenics Purchase Agreement [Member] | Royalty Payable in Longer Than10 Years [Member]              
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Percentage of royalty payable         3.50%    
Accounts Payable | Research, Development And Manufacturing Agreements With Samsung [Member]              
Loss Contingencies [Line Items]              
Contractual Obligation         $ 38,100,000    
Contractual Obligation, Fiscal Year Maturity [Abstract]              
Total         $ 38,100,000